Profound Medical Corp
NASDAQ:PROF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
International General Insurance Holdings Ltd
NASDAQ:IGIC
|
JO |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (29.4), the stock would be worth $-44.15 (764% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.4 | $6.65 |
0%
|
| Industry Average | 29.4 | $-44.15 |
-764%
|
| Country Average | 14.5 | $-21.72 |
-427%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Profound Medical Corp
NASDAQ:PROF
|
331m USD | -4.4 | -5.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
168.1B USD | 20 | 26.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
166.6B USD | 54.3 | 58.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
131.3B USD | 25 | 40.5 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.6B USD | 19.3 | 24 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
95.3B USD | 26.2 | 32.9 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.9B EUR | 16.3 | 20.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47B USD | 26.1 | 43.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
47B USD | 34.7 | 44.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.1B USD | 17.1 | 25.7 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
34B USD | 14.2 | 16.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.6 |
| Median | 14.5 |
| 70th Percentile | 20.6 |
| Max | 3 794.4 |
Other Multiples
Profound Medical Corp
Glance View
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
